Opus Dei
(Saint Josemaría)
First Women Scientists Receive Guadalupe Scholarships
The first women scientists from Africa who carried out research thanks to the Guadalupe Scholarship Program sponsored by Harambee were Dalene Kembabazi from Uganda and Celine Tendobi from D.R.Congo.
Recent News
Dalene Kembabazi
The Guadalupe scholarship enabled Dalene Kembabazi to fulfill her dream of specializing in public health measures to plan for and fight against pandemics like the current coronavirus.
“Postgraduate studies have opened my eyes to the system of public health in this country and worldwide, and I’m preparing myself to make a positive contribution to society in this important area. I consider it a privilege to be able to pursue a degree in the Makerere University School of Public Health, which is the principal institute working to control the Covid-19 pandemic in Uganda.”
Anti-parasitic Drug Ivermectin Reduces COVID-19 Transmission by Karishma Abhishek on January 20, 2021 at 9:05 PM
Early administration of Ivermectin can decrease the viral loads and symptom duration in patients with mild COVID-19. This may in turn lead to reduce viral transmission as per a small pilot study which is part of the SAINT project and has been led by the University of Navarra Clinic and the Barcelona Institute for Global Health (ISGlobal) published in the journal EClinicalMedicine, The Lancet. Many efforts are focusing on developing treatments for COVID-19, but few are addressing how to reduce viral transmission, says study coordinator Carlos Chaccour, researcher at ISGlobal and physician at the University of Navarra Clinic.
Credit: ISGlobal/Clínica Universidad de Navarra.
A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission. The study, which is part of the SAINT project and has been led by the University of Navarra Clinic and the Barcelona Institute for Global Health (ISGlobal), an institution supported by the la Caixa Foundation, warrants further exploration in larger clinical trials. The findings of the pilot study have been published in
EClinicalMedicine, a clinical journal published by The Lancet.
We already have two approved COVID-19 vaccines in the European Union, but immunising enough people worldwide to stop viral spread will require at least two years. Meanwhile, finding drugs that can treat or prevent infections remains a priority. Many efforts are focusing on developing treatments for COVID-19, but few are addressing how to reduce viral transm